Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 68 Tw Alexander Dr PO Box 13628 RESEARCH TRIANGLE PARK NC 27709 |
Tel: | N/A |
Website: | https://fennecpharma.com |
IR: | See website |
Key People | ||
Rostislav C. Raykov Chief Executive Officer, Director | Robert C. Andrade Chief Financial Officer | Adrian J. Haigh Chief Operating Officer |
Business Overview |
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. |
Financial Overview |
For the fiscal year ended 31 December 2023, Fennec Pharmaceuticals Inc revenues increased from $1.5M to $21.3M. Net loss decreased 32% to $16M. Revenues reflect Gross product revenues increase from $1.8M to $23.8M. Lower net loss reflects United States segment loss decrease of 43% to $12.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.90 to -$0.60. |
Employees: | 36 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $393.92M as of Dec 31, 2023 |
Annual revenue (TTM): | $29.04M as of Dec 31, 2023 |
EBITDA (TTM): | -$17.45M as of Dec 31, 2023 |
Net annual income (TTM): | -$21.93M as of Dec 31, 2023 |
Free cash flow (TTM): | -$23.43M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $22.86M as of Dec 31, 2023 |
Shares outstanding: | 27,099,908 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |